• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov13
Lyell Immunopharma released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 15K (forecast USD 0), actual EPS USD -2.1264 (forecast USD -2.6425)
04:00
Lyell Immunopharma released FY2025 9 Months Earnings on November 12 EST, with actual revenue of USD 30 K and EPS of USD -8.5528
04:00
Nov12
Lyell Initiates Phase III Clinical Trial for CAR T Cell Therapy in Aggressive B-Cell Lymphoma
21:05
Aug13
Lyell Immunopharma released FY2025 Semi-Annual Earnings on August 12 (EST), actual revenue USD 15K, actual EPS USD -6.422
03:00
Lyell Immunopharma released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 8 K (forecast USD 0), actual EPS USD -2.8854 (forecast USD -3.5833)
03:00
Jun26
Lyell Immunopharma Issues 625,000 Shares to ImmPACT Bio
20:07

Schedules & Filings

Schedules
Filings
Nov12
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 15 K, Net Income -38.85 M, EPS -2.1264

Aug12
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 8 K, Net Income -42.68 M, EPS -2.8854

Jun2
Reverse Stock Split(EST)

1-for-20 Reverse Stock Split

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
FJET
8.500
+136.77%
+4.910
AFJK
52.230
+100.81%
+26.220
DJTU
5.160
+83.63%
+2.350
ATHA
6.720
+62.52%
+2.585
SOC
8.250
+56.25%
+2.970
ZNB
1.020
+55.73%
+0.365
VIVK
0.0751
+47.25%
+0.024
SGD
0.2518
+42.26%
+0.075
DJT
14.860
+41.93%
+4.390
VSME
0.1035
+38.37%
+0.029
View More